News
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.
The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...
12hon MSN
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...
Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...
Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...
Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...
(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...
4d
Asianet Newsable on MSNGilead, Global Fund Enter Agreement To Supply HIV Prevention Drug To Low & Lower-Middle-Income CountriesUnder the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three ...
Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...
A landmark breakthrough in HIV prevention received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had started ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results